Advaxis, Inc. (ADXS) Social Stream



Advaxis, Inc. (ADXS): $0.03

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

D

Add ADXS to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#224 of 492

in industry

AYALA PHARMACEUTICALS INC (ADXS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ADXS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2023-08-11 1 $4 $4 $4 $0.65 515.38%
NA 1 $NA $NA $NA $0.65 NA%

Price Target Last Issued NA NA, NA

The Trend in the Analyst Price Target


Over the past 42 months, ADXS's average price target has gone down $1.

Over the past 73 days, ADXS's average upside potential has been 275.44%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-05-30 1 4 4 4 1.00 300%
2023-08-11 1 4 4 4 1.14 250.88%

ADXS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3 0 0 1 0 0 1

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • AYALA PHARMACEUTICALS INC's number of analysts covering the stock is higher than practically none of all US stocks.
  • In the context of all US stocks, AYALA PHARMACEUTICALS INC's variance in analysts' estimates is lower than almost 100% of them.
  • AYALA PHARMACEUTICALS INC's average analyst price target is greater than 4.41% of Healthcare stocks.
  • ADXS has a higher upside potential (average analyst target price relative to current price) than 83.97% of stocks in the small market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to AYALA PHARMACEUTICALS INC are NWBO, CBAY, and SEEL.

Is ADXS a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!